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Abstract 
Infectious diseases are a significant cause of morbidity and mortality across the world, and there are 
unique features of life in densely populated cities that make them a particular challenge. They may lead 
to short or long term illness, with direct healthcare costs and indirect losses in workforce productivity. 
The use of high-throughput sequencing technologies will allow cities to respond to these challenges on a 
number of levels. These include human genome sequencing at birth to predict infectious disease 
susceptibility; genetic surveillance and epidemiology to track emerging infectious diseases; genetic 
monitoring to ensure the success of vaccine strategies and to prevent the spread of antimicrobial 
resistance; and genetic diagnosis of infectious disease. Cities of the future must bring together clinical, 
research and industrial stakeholders to join different pieces of technology and research into a coherent 
health strategy. Sequencing-based management of infectious diseases has the potential to improve the 
health and quality of life of residents of future cities, even as populations grow in size and density, and 
become increasingly globalised. High-throughput sequencing is essential for the continued positive 
development of cities such as Singapore over the next 50 to 100 years, and beyond. 
Main text 
Imagine a scene in a future Singapore: with your genome sequenced a few years ago you know that you 
have a common genetic variant that puts you at increased risk of severe influenza, and you undergo 
regular monitoring. While you have been vaccinated against strains circulating this year your doctor 
takes a sample of your saliva and less than an hour later you could have a list of all of the pathogens 
currently present in your body. The centralised system compares all of the pathogens in your body and 
those circulating in routine tests in your neighbourhood. Any new pathogen strains with pathogenic 
potential can be readily picked up. You, your family and your co-workers can be supplied with 
prophylactic antivirals. This system would be able to prevent individual sickness, formation of drug 
resistance, and outbreaks. 
Every part of this scenario is currently possible in a lab, but at present we lack the understanding and 
infrastructure to pull these technologies and applications together. With population densities rising, if 
we are to maintain and improve on current standards of living we have no choice to but embrace a truly 
unified sequencing system for infectious disease epidemiology, diagnosis and management.  
The inhabitants of large cities are at risk from infectious diseases for a number of reasons. Large, mobile 
populations, typically living at high population densities, are the perfect melting pot for infectious 
diseases. These range from the short-term and typically mild (colds, food poisoning) to the chronic 
(tuberculosis) and potentially deadly (epidemics of emerging diseases such as SARS or new strains of 
influenza). All of these infectious diseases have impacts, including financial costs. Acute respiratory and 
gastrointestinal infections affect millions of working adults every year and lead to significant reductions 
in productivity. Norovirus outbreaks are estimated to cost the UK’s National Health Service (NHS) £100 
million per annum, and food poisoning results $2 billion per annum in lost productivity to the US 
economy. Cities at low latitudes have to contend with a burden of vector-driven infectious diseases such 
as malaria or dengue, with further costs. Antimicrobial and antiviral resistance is a growing problem at 
every level of the healthcare system, affecting every part of the population, and will lead to significant 
morbidity and mortality over the next century if not adequately managed. 
It is well-known that urbanisation creates ideal circumstances for epidemic diseases to become endemic 
ones, and for infections to spread rapidly through a population. The story of HIV might be very different 
without the introduction of this virus to the cities of Kinshasa and Brazzaville in the Democratic Republic 
of Congo at the start of the 20th century1. More recently, Reuters reported the introduction of Middle 
East Respiratory Syndrome (MERS) to South Korea, the result of global air travel.  
These challenges can all be met by better access to genetic data, which can be accessed through high-
throughput sequencing (HTS) technology (also known as next-generation sequencing). HTS gives 
researchers access to rich data that has obvious applications in a health care setting: the complete 
genome sequence of the patient; the pathogens present in a sample, known and unknown 
(metagenomics); and for known pathogens, HTS can provide evidence of antimicrobial or antiviral 
resistance within those pathogens. Future developments in HTS, and the increasing penetrance of these 
technologies into healthcare will have a significant impact on the way we manage infectious disease. 
In order for future cities to leverage these new technologies to maximum effect, I propose sequencing at 
every level: sequencing of the human genome at birth to predict which pathogens the population is 
particularly at risk from, and to allow personalised medicine; sequencing of pathogens during disease 
outbreaks; and sequencing-based surveillance in sentinel or reservoir groups, namely children, the 
elderly and the immunocompromised. Furthermore, sequence data combined with information 
technology will be able to predict which genes from new pathogens make good vaccine candidates. I will 
explore each of these applications in turn. 
Personalised medicine: genome sequencing to predict infection susceptibility 
Work over the last decade has shown that human genetic factors contribute to the susceptibility of 
many infectious diseases: dengue2, 3; influenza4, tuberculosis5 and HIV6. If an individual has their genome 
sequenced at birth, they could be counselled that they are at risk of certain infections (eg hepatitis C); 
vaccinated and screened regularly for infections that have long latency periods (TB); and targeted for 
vaccination during outbreaks (eg influenza and dengue). 
For individuals, this approach would save money by preventing hospitalisations and lost workforce 
productivity. The cost of a human genome sequence is now below $1000; compare this to a day spent in 
intensive care (estimated at $2300-3100 per day by the UK NHS) and it is clear how host genomics could 
be combined with public health measures to reduce health care costs. On a population level, 
understanding which diseases the population is most at risk from may help with disease forecasting, 
deciding which vaccines and drugs to prioritise, and even in shaping the research focus of laboratories 
towards the biggest infectious disease threats for the population. For example, the severe influenza 
susceptibility polymorphism rs12252 in IFITM34 is present in 0.3% of healthy Europeans but is found in 
5.7% of UK patients hospitalised with severe influenza. This polymorphism is much more common in 
parts of Asia (25% of healthy Han Chinese and 44% of healthy Japanese) and was found in 69% of 
patients hospitalised with severe H1N1 flu in Beijing7. Influenza pandemics may therefore present a 
greater public health threat in parts of Asia where this mutation is common and cities in these regions 
could introduce universal free influenza vaccination programmes each year to reduce the burden of 
disease.  
Sequencing for antibiotic resistant bacteria, drug resistant viral isolates, and transmission chains 
Sequencing can be used in the monitoring, diagnosis and management of many viral and bacterial 
pathogens relevant to cities such as New York, Beijing, Singapore and London. Using TB as an example, 
the power of new sequencing technologies is being brought to bear on the cause of this increasingly 
urban disease, Mycobacterium tuberculosis.  
The UK’s Health Protection Agency recently reported that London has TB rates of 42 per 100,000 people 
(four times the average for the UK) and considerably higher than other European cities such as Paris 
(23/100,000) and Copenhagen (17/100,000), but comparable to Singapore. One area of London had 119 
cases of TB per 100,000 people, higher than the average for India or Russia. Understanding how TB 
spreads and evolves multi-drug resistance are vital to managing this pathogen. High-throughput TB 
sequencing can: reduce the time from diagnosis to drug resistance testing from months to days, while 
also increasing the resolution and sensitivity of resistance testing8; distinguish between individuals who 
failed TB treatment and those who were successfully treated but became re-infected9; and rapidly 
validate transmission links between patients that were previously only inferred epidemiologically10. 
Beyond TB, sequencing can be used to track outbreaks of infection in healthcare settings, for example a 
norovirus outbreak within a children’s hospital11; or demonstrate that a pathogen has been circulating in 
an area for longer than observed disease would suggest. For example, sequencing showed that a strain 
of dengue virus had been present in Jeddah and wider Saudi Arabia before the index case presented to 
hospital; furthermore, whole genome sequence data was able to establish the likely origin of this strain 
(Africa) and a potential transmission route (pilgrims)12. Worldwide infectious disease monitoring in 
highly technologically developed cities may even act as a proxy for surveillance in less developed 
regions13.  
Sequencing is just as important for detecting infectious diseases of unknown origin, and has been used 
to identify the aetiological agent of previously undescribed human pathogens including SARS14 and 
MERS15. It can also be used to diagnose individual patients16. There are many diseases thought to have 
an infectious aetiology but for which a particular pathogen cannot be unambiguously implicated such as 
Kawasaki disease, a paediatric disease most common in Asian countries. Future cities can and must 
harness routine sequencing to deal with these threats to individual and public health.   
Sequencing pathogens to ensure vaccine efficacy 
Sequencing technology has an important role to play in managing vaccine-preventable diseases, for 
example in ensuring that vaccines provide protection against circulating pathogen diversity, or by 
identifying whether live attenuated vaccines are recombining with wild-type strains to cause disease 
themselves. 
Individuals co-infected with hepatitis B virus (HBV) and HIV provide the ideal circumstances for HBV to 
mutate and escape from current vaccine protection, as these co-infected individuals provide the perfect 
storm of poor immune responses, chronic infection requiring antiviral treatment for HBV, and a lifestyle 
that may include many of the risk factors for onwards HBV transmission, such as intravenous drug use17. 
Sequencing of HBV in sentinel groups such as the HIV/HBV co-infected can track the evolution and 
transmission of these escape mutants. However, HBV vaccine escape mutants also circulate naturally 
within the population, including in immunocompetent children18. A sequencing-based strategy to 
eradicate HBV would combine surveillance of all newly-vaccinated individuals and high-risk groups to 
ensure that the antigens in the HBV vaccine continue to provide protection as new escape mutants are 
detected. 
Monitoring of live attenuated vaccine recombination with wild-type strains is being actively performed 
for the varicella-zoster vaccine with prevents the childhood and old-age manifestations of this common 
viral infection: chicken pox (varicella), and shingles (zoster). While no wild-type-vaccine recombination 
events have yet been found19, it is a real possibility and may require a change a different vaccine 
strategy which will not allow recombination (eg a subunit vaccine or virus-like particle approach). 
Pathogen sequencing for diagnosis and treatment management 
Cities of the future, such as Singapore, can lead the way in integrating the approaches discussed above, 
because they can take the best new technologies developed by researchers and industry, and integrate 
them into health care systems. This will include developing standard operating procedures for sampling 
appropriate material (environmental, animal or human) on a rapid-turnaround sequencing platform. 
This method would need to capture all aspects of pathogen genetic material (DNA and RNA) and 
sequence them to high depth. The pipeline would then include automated bioinformatic analysis of the 
sample’s genetic contents, with results scored against a database of known and potential pathogens to 
aid physician diagnosis. If this sequencing is sufficiently optimised and high coverage, it may even be 
possible to automate diagnoses and suggestion of drug treatments. For viral pathogens such as HIV and 
cytomegalovirus, there are published, well-characterised lists of mutations conveying resistance to 
particular drugs. The same is true of some bacterial pathogens. Patients would only be treated with drug 
to which their infection remains sensitive. 
Regular molecular surveillance is an important part of infectious disease control for future cities. This 
could include taking nasopharyngeal swabs from every person attending primary healthcare as part of 
the standard work-up. School children and healthcare workers could be sampled regularly, as children 
are a significant reservoir of influenza-like illnesses. This would provide high-resolution epidemiological 
sampling, with the potential to identify emerging infectious diseases before they become a significant 
problem. For example, phylogenetic analysis has revealed that the 2009 swine flu outbreak in the UK 
was caused by a strain of influenza that was circulating in the UK for several months before the first 
clinical case was diagnosed20. Molecular epidemiology of norovirus suggests that asymptomatic or 
chronic norovirus carriers, who may be elderly, malnourished or immune compromised, form a reservoir 
for this disease21. If molecular surveillance methods are used, scientists have the potential to detect 
novel, perhaps pandemic, disease outbreaks before they come to the notice of healthcare services. This 
would allow for better pandemic preparedness or quarantine for infection control. 
The technology required to maintain these kinds of surveillance and response-based sequencing are 
gradually diffusing from large, dedicated sequencing centres such as BGI (Beijing Genomics Institute) 
China, the Broad Institute USA, A*STAR Singapore and the Wellcome Trust Sanger Institute UK to clinical 
settings in large urban areas. There are numerous hospitals pushing forward sequencing-based 
infectious disease management and diagnostics within the UK, mostly in or within 100 miles of London. 
These include Addenbrookes Hospital in Cambridge, and Great Ormond Street Hospital for Children and 
University College Hospital, both London. These hospitals greatly benefit from a close, synergistic 
working relationship between basic and translational research, bringing together academic, industrial, 
governmental and clinical partners. Similar models for treatment are emerging in other major urban 
areas around the world and represent the future of this kind of healthcare. 
In our increasingly globalised cities, we see a melting pot of people – and pathogens – from all over the 
world. This diversifies the pathogens to which everyone is at risk and makes epidemiological forecasting 
increasingly challenging. Genetic surveillance and management of infectious diseases must become the 
new gold standard for preventing and controlling infectious disease in cities of the future.  
Preventative medicine 
Looking further into the future, large genetic datasets of diverse pathogens would allow computers to 
predict which proteins produced by novel pathogens make good vaccine candidates. Vaccines could be 
synthesised on a personalised basis for prevention or therapy, allowing the infected or exposed 
individual to mount a more directed immune response. Similar database and computational prediction 
could provide physicians with a list of known drugs the pathogen is likely to respond to. 
Vaccines or drugs could be made available to the whole population if an infectious disease has epidemic 
potential, before such an epidemic starts. The vast majority of infectious diseases circulate for months 
or even years at a time before an outbreak occurs or they are detected by health care systems. By 
detecting these pathogens at the earliest opportunity, their ability to further adapt to humans can be 
curtailed. 
Future cities are uniquely placed to bring all these technologies together to improve the health and well-
being of their populations. They have the critical mass of knowledge and capacity from industry, 
research and medical care to unify the technologies and implement them in systems supported by the 
state to deliver solutions. While living in ever-denser cities presents a range of challenges for future 
governments and states, it is within our power to overcome them. 
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